NICE is consulting again on the use of lenalidomide (Revlimid, Celgene) for treating the blood cancer multiple myeloma after one prior treatment with bortezomib. With the further information provided by the manufacturer, the committee’s new draft guidance still does not recommend lenalidomide for this indication.
31 July 2014
On World Hepatitis Day NICE has issued a new quality standard aimed at preventing transmission of hepatitis B and improving the lives of those living with the condition.
27 July 2014